TTX-080-001 A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080, an HLA-G Antagonist, as Monotherapy and in Combination with Pembrolizumab or Cetuximab in Patients with Advance Solid Refractory/Resistant Malignancies

NCT04485013

A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080, an HLA-G Antagonist, as Monotherapy and in Combination with Pembrolizumab or Cetuximab in Patients with Advance Solid Refractory/Resistant Malignancies

Associated Conditions

Multiple Tumor Types

Sponsor

Tizona Therapeutics, Inc.

This study is currently enrolling.